Blinatumomab for Relapsed Acute B Lymphoblastic Leukemia After Transplantation

NCT06339775 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Acute B-cell Lymphoblastic Leukemia

Interventions

DRUG: Blinatumomab

Sponsor

Suping ZHANG